This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Coronavirus Ups the Game for Robotic Surgery: 3 Stocks on Radar
by Sriparna Ghosal
Let's keep a watch on the potentially strong three MedTech stocks, namely SYK, ARAY and MDT with respect to robotic-assisted surgery that showed promises during the pandemic.
Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging
by Zacks Equity Research
Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.
Integra (IART) Sells Unprofitable Arm to Focus on Core Business
by Zacks Equity Research
Integra (IART) does not expect the selloff to have a material impact on its 2020 results.
Integra (IART) to Buy ACell, Expand Regenerative Capability
by Zacks Equity Research
Integra (IART) expects to close the ACell acquisition in the first quarter of 2021, subject to fulfilment of closing conditions.
Is Smith & Nephew (SNN) a Suitable Stock for Value Investors?
by Zacks Equity Research
Let's see if Smith & Nephew plc (SNN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Robot-Assisted Surgery Gains Momentum Amid Coronavirus
by Trina Mukherjee
Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.
Smith+Nephew Unveils Digital Platform to Boost Patient Care
by Zacks Equity Research
With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.
Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark
by Zacks Equity Research
We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.
Smith & Nephew's JOURNEY II UK Knee System Executes Surgeries
by Zacks Equity Research
The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.
Smith & Nephew's Study Outcomes for REGENETEN Encouraging
by Zacks Equity Research
Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.
Smith & Nephew's (SNN) STITCH Study Outcome Encouraging
by Zacks Equity Research
This can be considered a major step in Smith & Nephew's (SNN) commitment toward strengthening its Global Sports Medicine and ENT segment.
Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining from several positive developments of late.
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
by Zacks Equity Research
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
Smith & Nephew (SNN) Buys Brainlab, Braces Robotic Ecosystem
by Zacks Equity Research
The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.
Titan Medical (TMDI) Shows Promise on Strategic Developments
by Zacks Equity Research
Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.
Here's Why You Should Invest in Smith & Nephew (SNN) Now
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining investor confidence on consistently positive results.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
Is Britain Headed for a Soft Brexit? 5 Picks
by Swarup Gupta
Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.
Smith & Nephew (SNN): Moving Average Crossover Alert
by Zacks Equity Research
Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.
Medical Device Industry Outlook - February 2018
by Zacks Equity Research
Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.
MedTech Tax Resumes in 2018, 3 Stocks to Suffer
by Zacks Equity Research
Sectors that are likely to be hampered the most by the re-imposition of the medical device tax are X-ray and MRI machines, surgical instruments and pacemakers.
Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm
by Zacks Equity Research
Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew